AstraZeneca CEO Says Inversion Rules Undercut Pfizer Bid

The CEO of AstraZeneca PLC said Thursday that recent U.S. tax rules diminish the benefits of inversion deals like the one Pfizer Inc. pitched to it earlier this year, dimming the...

Already a subscriber? Click here to view full article